This study looked at adding thymosin alpha1 to standard medical therapy for patients with hepatitis B virus-related acute-on-chronic liver failure. The trial included 73 patients and followed them for 90 days. The researchers found that the group receiving thymosin alpha1 had significantly higher rates of transplant-free survival compared to those on standard therapy alone. They also observed reductions in certain immune cell frequencies and a moderation of late-stage inflammatory responses.
The study was conducted as an open-label trial, meaning both the patients and doctors knew who received the new treatment. Specific numerical outcomes, p-values, and confidence intervals were not reported in the available abstract. No adverse events or discontinuations were reported in the safety data provided.
Readers should be cautious because the sample size was small and the design lacks the blinding usually needed to confirm results. While the findings suggest a potential link between the drug and better survival, the magnitude of the benefit and long-term safety are not yet clear. This evidence is too early to change standard medical practice.
